SAN FRANCISCO – Nine studies exploring a variety of trends and approaches in immuno-oncology, including adaptive cell therapies, immune checkpoint inhibitors, the use of predictive biomarkers, and more, will be presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The meeting will take place February 28 – March 2 at the San Francisco Marriott Marquis in San Francisco, California.

Experts in immuno-oncology are available to comment on the studies below.

**Abstract 30:** *The effect of adoptive transfer of ex vivo activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.*

**Poster Session A**
- Thursday, February 28, 2019: 11:30 a.m. - 1:00 p.m. PT
- Thursday, February 28, 2019: 6:00-7:00 p.m. PT
- Golden Gate Hall, B2 Level

Patrick C. Gedeon, PhD  
Duke University Medical Center  
Durham, North Carolina

**Abstract 45:** *Epigenetic biomarkers for noninvasive detection of colorectal cancer.*

**Poster Session B**
- Friday, March 1, 2019: 11:30 a.m. - 1:00 p.m. PT
- Friday, March 1, 2019: 5:30-6:30 p.m. PT
- Golden Gate Hall, B2 Level

Dhruvajyoti Roy  
Laboratory for Advanced Medicine, Inc.  
Irvine, California

**Abstract 74:** *Enhanced antitumor effect and lower viral reactivation with high doses of ex vivo expanded NK cells administered after haploidentical transplantation.*
Abstract 99: Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial.

Abstract 102: Characterizing the T cell repertoire in lung squamous cell premalignancy and its association with lesion outcome.


Abstract 120: Estimated costs of grade 3–4 all-cause and treatment-related adverse events for stage IV or recurrent non-small cell lung cancer (NSCLC) in the CheckMate 227 (CM-227) trial.
Abstract 136: Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.

Abstract 152: Isolation and characterization of exosomes from IDH mutant gliomas.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer
cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO’s Conquer Cancer Foundation supports the Society by funding groundbreaking research and education across cancer’s full continuum. Learn more at [www.ASCO.org](http://www.ASCO.org), explore patient education resources at [www.Cancer.Net](http://www.Cancer.Net), and follow us on Facebook, Twitter, LinkedIn, and YouTube. The Society is led by President Monica M. Bertagnolli, MD, FACS, FASCO, of the Dana-Farber/Brigham and Women’s Cancer Center, and CEO Clifford A. Hudis, MD, FACP, FASCO. [Learn more](http://www.ASCO.org) about ASCO.

**About the Society for Immunotherapy of Cancer:**
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.

[Learn more about SITC](http://www.sitc-oncology.org), its educational offerings and other resources.